Lacosamide Controlled Release Formulation for Once-Daily Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lacosamide formulations for treating epilepsy are limited by rapid plasma concentration fluctuations, leading to increased side effects and the need for twice daily administration, which is inconvenient and may not effectively manage severe seizures.
Innovation Solution
A controlled release formulation of lacosamide that slows the release of the drug to achieve a steady-state plasma concentration, reducing peak-to-trough fluctuations and allowing for once daily administration with improved side effect profiles and maintained efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation is used, then rapid absorption and onset of action is achieved, but plasma concentration fluctuations increase leading to side effects and requiring twice daily administration
Solution Approach 1:
The patent applies dynamics by transitioning from a static immediate-release formulation to a dynamic controlled-release formulation that adjusts drug release over time. The osmotic pump mechanism creates a dynamic system where the release rate is controlled by osmotic pressure gradients, allowing the formulation to maintain steady plasma concentrations throughout the dosing interval rather than showing rapid peaks and troughs.
Solution Approach 2:
The patent changes the release rate parameter from rapid (immediate release) to controlled (zero-order or sustained release). By modifying the formulation to include osmotic agents and controlled-release matrices, the drug release parameter is transformed from fast absorption to sustained release, thereby maintaining stable plasma concentrations and reducing side effects associated with peak concentrations.
2Reliability
If immediate release formulation is used, then therapeutic efficacy is achieved, but administration frequency must be twice daily reducing patient convenience
Solution Approach 1:
The patent implements continuity of useful action by designing a controlled-release formulation that provides sustained drug release over an extended period (24 hours or more). The osmotic pump system ensures continuous release of lacosamide at a controlled rate, maintaining therapeutic plasma concentrations throughout the entire dosing interval without requiring repeated administration, thus improving patient convenience while preserving efficacy.
3Ease of operation
If controlled release formulation is developed, then once daily administration is enabled, but formulation complexity increases
Solution Approach 1:
The patent uses an osmotic agent as an intermediary substance that facilitates controlled drug release without requiring complex mechanical components. The osmotic agent (e.g., sodium chloride, sucrose) creates osmotic pressure gradients that drive the release of lacosamide through a semi-permeable membrane, providing a simple yet effective mechanism for controlled release that avoids the need for complex pumps or valves.
Solution Approach 2:
The patent simplifies the controlled-release mechanism by changing the formulation parameters to rely on passive osmotic diffusion rather than active pumping or complex release mechanisms. By adjusting the osmotic agent concentration, membrane permeability, and matrix composition, the formulation achieves controlled release through fundamental physical principles, reducing manufacturing and formulation complexity.
Data Source
AI summary
A modified release formulation of lacosamide suitable for once-daily administration.